FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891983275> ?p ?o ?g. }

• W2891983275 endingPage "20" @default.
• W2891983275 startingPage "15" @default.
• W2891983275 abstract "Introduction: Degree of skin penetration of topical drugs and cosmetics is a crucial point concerning their effects and tolerability. For testing drug delivery across the dermal barrier different in vitro and in vivo assays have been developed. Caffeine has been shown to have beneficial effects against skin aging, sunburn and hair-loss, and it is protective against melanoma and non-melanoma type skin cancers. Aim of our study was to set up an assay system to evaluate caffeine penetration from topical formulation into the skin. </P><P> Methods: Franz diffusion cells consisting of either a filter paper or an artificial membrane or rat skin were used as in vitro/ex vivo test systems and transdermal microdialysis in anaesthetized rats was performed as an in vivo assay. </P><P> Results: Results indicate that Franz diffusion cell studies provide a good approximation of the release of caffeine from the formulation but are not able to differentiate between 2% and 4% cream concentrations. The maximum concentrations (Cmax) in case of the 2% cream formulation were 708.3 (2.7 μm pore), 78.7 (0.8 &#181;m pore), 45.3 (0.45 &#181;m pore) and 44.9 (rat skin) &#181;g/7.5 mL, respectively. The in vivo microdialysis experiments were in accordance with the in vitro and ex vivo results and gave more information on the dynamics and follicular and transcellular phases of drug penetration through the layers of the skin. </P><P> Discussion and Conclusion: Taken together, Franz diffusion cell and transdermal microdialysis are a good combination to evaluate caffeine release and penetration into the skin from the formulations tested. This system might also be used for rapid testing of other hydrophilic topical drugs and has a benefit in the prediction for human skin absorption and tolerability studies, in an early phase of drug development." @default.
• W2891983275 created "2018-09-27" @default.
• W2891983275 creator A5000586830 @default.
• W2891983275 creator A5003963129 @default.
• W2891983275 creator A5039251303 @default.
• W2891983275 creator A5046821634 @default.
• W2891983275 creator A5058012449 @default.
• W2891983275 creator A5063522393 @default.
• W2891983275 date "2019-02-06" @default.
• W2891983275 modified "2023-10-18" @default.
• W2891983275 title "Validation of an In vitro-in vivo Assay System for Evaluation of Transdermal Delivery of Caffeine" @default.
• W2891983275 cites W1946930581 @default.
• W2891983275 cites W1980623161 @default.
• W2891983275 cites W1985644326 @default.
• W2891983275 cites W1997880497 @default.
• W2891983275 cites W2000266947 @default.
• W2891983275 cites W2009284487 @default.
• W2891983275 cites W2031967897 @default.
• W2891983275 cites W2048780311 @default.
• W2891983275 cites W2057306840 @default.
• W2891983275 cites W2058625468 @default.
• W2891983275 cites W2068228356 @default.
• W2891983275 cites W2069057826 @default.
• W2891983275 cites W2069840236 @default.
• W2891983275 cites W2071147039 @default.
• W2891983275 cites W2072965128 @default.
• W2891983275 cites W2094073351 @default.
• W2891983275 cites W2101695368 @default.
• W2891983275 cites W2340906760 @default.
• W2891983275 cites W2407092926 @default.
• W2891983275 cites W2604184065 @default.
• W2891983275 cites W2606830774 @default.
• W2891983275 cites W2773644057 @default.
• W2891983275 cites W2790912645 @default.
• W2891983275 doi "https://doi.org/10.2174/2210303108666180903102107" @default.
• W2891983275 hasPublicationYear "2019" @default.
• W2891983275 type Work @default.
• W2891983275 sameAs 2891983275 @default.
• W2891983275 citedByCount "8" @default.
• W2891983275 countsByYear W28919832752019 @default.
• W2891983275 countsByYear W28919832752020 @default.
• W2891983275 countsByYear W28919832752021 @default.
• W2891983275 countsByYear W28919832752022 @default.
• W2891983275 countsByYear W28919832752023 @default.
• W2891983275 crossrefType "journal-article" @default.
• W2891983275 hasAuthorship W2891983275A5000586830 @default.
• W2891983275 hasAuthorship W2891983275A5003963129 @default.
• W2891983275 hasAuthorship W2891983275A5039251303 @default.
• W2891983275 hasAuthorship W2891983275A5046821634 @default.
• W2891983275 hasAuthorship W2891983275A5058012449 @default.
• W2891983275 hasAuthorship W2891983275A5063522393 @default.
• W2891983275 hasConcept C112705442 @default.
• W2891983275 hasConcept C126322002 @default.
• W2891983275 hasConcept C127413603 @default.
• W2891983275 hasConcept C142724271 @default.
• W2891983275 hasConcept C150903083 @default.
• W2891983275 hasConcept C185592680 @default.
• W2891983275 hasConcept C202751555 @default.
• W2891983275 hasConcept C205679159 @default.
• W2891983275 hasConcept C207001950 @default.
• W2891983275 hasConcept C22979827 @default.
• W2891983275 hasConcept C26291073 @default.
• W2891983275 hasConcept C2777459323 @default.
• W2891983275 hasConcept C2778370115 @default.
• W2891983275 hasConcept C2778500429 @default.
• W2891983275 hasConcept C42475967 @default.
• W2891983275 hasConcept C50156730 @default.
• W2891983275 hasConcept C54355233 @default.
• W2891983275 hasConcept C55493867 @default.
• W2891983275 hasConcept C71924100 @default.
• W2891983275 hasConcept C80107235 @default.
• W2891983275 hasConcept C86803240 @default.
• W2891983275 hasConcept C98274493 @default.
• W2891983275 hasConceptScore W2891983275C112705442 @default.
• W2891983275 hasConceptScore W2891983275C126322002 @default.
• W2891983275 hasConceptScore W2891983275C127413603 @default.
• W2891983275 hasConceptScore W2891983275C142724271 @default.
• W2891983275 hasConceptScore W2891983275C150903083 @default.
• W2891983275 hasConceptScore W2891983275C185592680 @default.
• W2891983275 hasConceptScore W2891983275C202751555 @default.
• W2891983275 hasConceptScore W2891983275C205679159 @default.
• W2891983275 hasConceptScore W2891983275C207001950 @default.
• W2891983275 hasConceptScore W2891983275C22979827 @default.
• W2891983275 hasConceptScore W2891983275C26291073 @default.
• W2891983275 hasConceptScore W2891983275C2777459323 @default.
• W2891983275 hasConceptScore W2891983275C2778370115 @default.
• W2891983275 hasConceptScore W2891983275C2778500429 @default.
• W2891983275 hasConceptScore W2891983275C42475967 @default.
• W2891983275 hasConceptScore W2891983275C50156730 @default.
• W2891983275 hasConceptScore W2891983275C54355233 @default.
• W2891983275 hasConceptScore W2891983275C55493867 @default.
• W2891983275 hasConceptScore W2891983275C71924100 @default.
• W2891983275 hasConceptScore W2891983275C80107235 @default.
• W2891983275 hasConceptScore W2891983275C86803240 @default.
• W2891983275 hasConceptScore W2891983275C98274493 @default.
• W2891983275 hasFunder F4320338080 @default.
• W2891983275 hasIssue "1" @default.
• W2891983275 hasLocation W28919832751 @default.

• next